target directory

cpx 351 cytarabine daunorubicin is designed to target acute leukemias and myelodysplastic syndromes mds through a liposomal formulation that enhances the pharmacokinetics and pharmacodynamics of its components clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.